Session » Cytokines and Cell Trafficking Poster

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0580

18F-FDG PET-MR Characterization of Aortitis in the IL1rn-/- Mouse Model of Giant-Cell Arteritis

9:00AM-10:30AM: Abstract Number: 0585

Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts

9:00AM-10:30AM: Abstract Number: 0579

Characterization of Terminal Uridyl Transferase Function in Response to Tumor Necrosis Factor-α in Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-10:30AM: Abstract Number: 0582

Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases

9:00AM-10:30AM: Abstract Number: 0587

Increase of Intercellular Adhesion Molecule-1 Linked to Lung Damage of Interstitial Lung Disease in Patients with Autoimmune Diseases

9:00AM-10:30AM: Abstract Number: 0578

Interleukin-6 Trans-Signaling Induces Synovial Fibroblast Invasiveness by Utilizing Ets2 Protein

9:00AM-10:30AM: Abstract Number: 0581

Mutants Improving Stability Enhance the Potency of Treg-Selective IL-2 Mutein for the Treatment of Autoimmune Disorders

9:00AM-10:30AM: Abstract Number: 0584

Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways

9:00AM-10:30AM: Abstract Number: 0588

S-nitrosoglutathione Reductase (GSNOR) Regulates Osteoclast Differentiation

9:00AM-10:30AM: Abstract Number: 0583

Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4

9:00AM-10:30AM: Abstract Number: 0586

Transcription Factor Fli-1 Impacts CXCL13 Expression and Renal Inflammation in Lupus-like Nephritis of Adult MRL/lpr Mouse

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].